Compare KALU & NVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KALU | NVAX |
|---|---|---|
| Founded | 1946 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 1.6B |
| IPO Year | 2006 | 1996 |
| Metric | KALU | NVAX |
|---|---|---|
| Price | $130.72 | $8.03 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 3 | 9 |
| Target Price | ★ $107.00 | $11.33 |
| AVG Volume (30 Days) | 166.3K | ★ 3.7M |
| Earning Date | 04-22-2026 | 05-07-2026 |
| Dividend Yield | ★ 2.56% | N/A |
| EPS Growth | 135.89 | ★ 309.76 |
| EPS | ★ 6.77 | 2.58 |
| Revenue | ★ $1,585,900,000.00 | $1,123,479,000.00 |
| Revenue This Year | $13.37 | N/A |
| Revenue Next Year | $2.62 | N/A |
| P/E Ratio | $17.83 | ★ $3.16 |
| Revenue Growth | N/A | ★ 64.69 |
| 52 Week Low | $46.81 | $5.01 |
| 52 Week High | $150.00 | $11.85 |
| Indicator | KALU | NVAX |
|---|---|---|
| Relative Strength Index (RSI) | 59.99 | 34.64 |
| Support Level | $116.89 | $8.01 |
| Resistance Level | $136.10 | $8.45 |
| Average True Range (ATR) | 5.10 | 0.55 |
| MACD | 1.43 | -0.28 |
| Stochastic Oscillator | 99.08 | 9.93 |
Kaiser Aluminum Corp specializes in the production of semi-fabricated specialty aluminum mill products, such as aluminum plate and sheet, bare and coated coil and extruded and drawn products, for the end market applications: Aero/HS Products; Packaging; GE Products; and Automotive Extrusions. Its products include fabricated aluminum mill products such as flat-rolled (plate, sheet, and coil), extruded (rod, bar, hollows, and shapes), drawn (rod, bar, pipe, tube and wire) and certain cast aluminum products. Geographically, the company generates majority of its revenue from the United States.
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, an in-house early-stage R&D business to build a pipeline of high-value assets using its technology along with seeking to enter into partnerships to drive value creation for its assets.